FDA Approves Rubraca® Expansion as Early Treatment for Prostate Cancer The FDA has granted expanded approval for Rubraca®, the first PARP inhibitor to outperform docetaxel, offering earlier treatment options for prostate cancer patients.

FDA Approves Rubraca® Expansion as Early Treatment for Prostate Cancer #USA #Buffalo_Grove #Tolmar #Rubraca #PARP_Inhibitor